Feasibility and cohort development for HIV vaccine trials in Haiti. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Feasibility and cohort development for HIV vaccine trials in Haiti.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S231-3. Unique Identifier : AIDSLINE MED/95169489
Deschamps MM; Johnson WD Jr; Pape JW; Groupe Haitien D'Etude du Sarcome de Kaposi et des Infections; Opportunistes (Gheskio), Port-au-Prince, Haiti.

Abstract: Human immunodeficiency virus (HIV) infection is spreading rapidly in Haiti with HIV seroprevalence rates of 10% and 3% in urban and rural areas, respectively. Since 1985, heterosexual transmission has been the primary mode of acquisition of HIV. From 1981 to the present, the Cornell-GHESKIO unit in Port-au-Prince, Haiti, has developed the infrastructure to recruit and retain large cohorts of individuals at risk for HIV infection. Among the populations studied, couples discordant for HIV infection appear most suitable for eventual HIV phase III vaccine trial. This paper describes the recruitment, retention, and characteristics of the discordant-couples cohort, as well as the limitations of interventions aimed at behavior modification.
Keywords: AIDS Vaccines/*PHARMACOLOGY Clinical Trials/*METHODS Cohort Studies Female Haiti Human HIV Infections/*PREVENTION & CONTROL/TRANSMISSION Male Patient Selection Sex Behavior Sexual Partners Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDaidsvaccines/KWDpharmacologyclinicaltrials/KWDmethodscohortstudiesfemalehaitihumanhivinfections/KWDprevention&control/transmissionmalepatientselectionsexbehaviorsexualpartnerssupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
950630
M9561127

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .